Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes. We hypothesized that the combined transfer of TIL,...

Full description

Bibliographic Details
Main Authors: Sapna Patel, Adi Diab, Michael A. Davies, Jennifer L. McQuade, Michael K. Wong, Isabella C. Glitza, Hussein A. Tawbi, Rodabe N. Amaria, Chantal Saberian, Enrique Alvarez, Amer M. Najjar, Laszlo G. Radvanyi, Cara L. Haymaker, Roland L. Bassett, Silvana C. Faria, Sapna Parshottam, Victor Prieto, Elizabeth J. Shpall
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002449.full

Internet

https://jitc.bmj.com/content/9/5/e002449.full

Similar Items